CMSC 2024: Optimizing Multiple Sclerosis Treatment

Annalisa Morgan, MD

Disclosures

June 28, 2024

Annalisa Morgan, MD, reflects on insights gained from the Consortium of Multiple Sclerosis Centers 2024 Annual Meeting regarding the management of multiple sclerosis (MS). She emphasizes the significance of data influencing clinical practice, particularly in patients with new-onset highly inflammatory relapsing-remitting MS, and although expecting to continue to favor an early high-efficacy therapy approach, acknowledges the potential for lower-efficacy therapies and an escalation approach in certain cases. 

Extended-interval dosing of anti-CD20 therapies, especially in patients experiencing side effects or those with well-controlled MS, is also considered. In regard to discontinuation of medications, Dr Morgan suggests that it may apply primarily to older patients with stable disease. Finally, the importance of lifestyle modifications and symptom management was not overlooked at the conference. Overall, Dr Morgan anticipates incorporating new findings into clinical practice and looks forward to future research to enhance MS care.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.

processing....